The Combating Illicit Xylazine Act places xylazine - a veterinary sedative increasingly found in illicit drug mixtures - into Schedule III of the Controlled Substances Act, subjecting it to federal regulation as a controlled substance. It specifically allows veterinary use without requiring registration of the ultimate user (e.g., pet owners or veterinarians) if xylazine is dispensed by a registered veterinarian or pharmacy with a vet prescription and used for animals owned by the user, under their care, or in authorized animal programs. The bill provides a one-year delay for labeling and packaging requirements and a 60-day delay for registration and recordkeeping for veterinary use to ease implementation. Additionally, it adds xylazine to the Arcos tracking system for controlled substances and mandates two congressional reports on illicit use prevalence within 18 months and 4 years of enactment.
This resolution designates June 6, 2025, as National Naloxone Awareness Day to raise public awareness about naloxone, a life-saving medication that reverses opioid overdoses. It urges federal, state, local governments, and organizations to improve access to naloxone and educate communities on its use, without creating new laws or funding. The resolution focuses on recognition and education, not policy changes or mandates.
This bill requires electronic communication service providers (like social media platforms) and remote computing services (like cloud storage) to report certain controlled substances violations to the Attorney General. Providers must submit reports within 60 days of discovering fentanyl, methamphetamine, or counterfeit prescription drug sales, including account information and details about the violation. The bill includes penalties for failure to report ($380,000 for repeat violations) and for submitting false reports ($100,000), while exempting broadband and text messaging providers from these requirements. It also mandates annual reports from the Attorney General on the number of reports received, investigations conducted, and how violations were discovered.
This bill amends U.S. sanctions law to target Chinese entities and officials involved in fentanyl trafficking. It redefines "foreign opioid trafficker" to include Chinese chemical companies or government officials (like those in the National Narcotics Control Commission) that fail to prevent fentanyl precursor trafficking or cooperate with U.S. efforts. Key mechanisms include requiring China to implement stricter chemical shipment labeling and "know-your-customer" procedures, extending sanctions periods from 5 to 10 years, and mandating annual presidential reports to Congress on drug trafficking emergencies. The bill explicitly excludes importation of goods from sanctions coverage.
The MORE Savings Act eliminates copays and deductibles for opioid treatment under Medicare, private health plans, and Medicaid. It requires Medicare beneficiaries to have no out-of-pocket costs for opioid treatment drugs, behavioral health services, and recovery support (like peer counseling and transportation). Private health plans must cover these services without cost-sharing starting in 2027, and Medicaid states get a 90% federal match for medication-assisted treatment. The bill directly affects Medicare beneficiaries, private insurance enrollees, and Medicaid recipients seeking opioid use disorder treatment.
HR 944, the Access to Counsel Act, requires U.S. immigration officials to provide certain immigrants a meaningful opportunity to consult with legal counsel during key immigration processes. It directly affects U.S. nationals, lawful permanent residents returning from travel, visa holders, refugees, asylees, and parolees subject to secondary or deferred inspection at ports of entry. The bill mandates that officials ensure access to counsel (including via phone) within one hour of inspection starting, allow counsel to present evidence, and accommodate in-person meetings when possible. It also requires officials to provide counsel access before accepting Form I-407 abandonment forms from lawful permanent residents, unless waived in writing. The law takes effect 180 days after enactment and preserves existing rights to counsel under other immigration laws.
The STATES 2.0 Act would allow states to regulate cannabis markets within their borders without federal interference, while establishing a low federal excise tax that doesn't compound with state taxes. It would amend the Controlled Substances Act to exempt state-legal marijuana activities from federal prosecution, remove marijuana from the federal controlled substances schedule for state-compliant activities, and allow the FDA to regulate marijuana products as food, drugs, or cosmetics. The bill would require a study on marijuana legalization's effects on traffic safety and address regulatory barriers contributing to the illicit market, which currently accounts for 75% of the marijuana market. This legislation directly affects states that have legalized cannabis, marijuana businesses, and consumers by creating a regulatory framework that supports state autonomy and reduces illegal market activity.
S 2242, the Counternarcotics Enhancement Act, requires U.S. intelligence agencies to strengthen collaboration with Mexico's government on counternarcotics efforts. Within 60 days of enactment, each intelligence agency must assess its existing relationships with Mexican counterparts and propose strategies for improved cooperation, including resource needs. The Director of National Intelligence must then compile these submissions and develop an unclassified action plan with recommendations for 2026, including potential authority or funding changes. This bill directly affects U.S. intelligence community elements and their coordination with Mexican government agencies on drug trafficking issues.
The BUMP Act (S 1374) bans devices that increase the firing rate of semiautomatic firearms to mimic machineguns, directly affecting owners of modified firearms. It prohibits importing, selling, or possessing devices (like "bump stocks") that speed up firing or eliminate the need for separate trigger pulls, and requires registration of existing modified semiautomatics within 120 days. The law exempts government agencies and pre-enactment modifications that are registered. This targets specific firearm modifications, not all semiautomatic weapons.
This bill requires states to cover medication-assisted treatment (MAT) for opioid use disorder under Medicaid without prior authorization or dosage limits for at least one formulation of each approved drug. It directly affects Medicaid patients with opioid use disorder and their healthcare providers, removing administrative barriers that previously required extra approvals or restricted dosing. The bill amends Medicaid law to mandate this coverage, while also requiring a federal report analyzing how current state policies (like dosing limits or counseling requirements) impact access to MAT. The changes apply starting one year after enactment, with states needing time to adjust if new state laws are required.